ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program

ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer